Neuralymed
1 known investors
Neuraly is a clinical-stage biotechnology company developing disease-modifying treatments for neurodegenerative diseases, with a focus on inhibiting pathological glial activation to prevent neuronal cell death. The company is advancing NLY01, a candidate in Phase 2 clinical trials for Parkinson's disease.
AI & Machine LearningBiotechMedical Devices